The notices it replaced
- Reissues: PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- 2 steps back: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 3 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 7 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 11 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 12 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-21-262.
Who won it before
1,563 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $518,999,501 in first-year total cost, median $251,344.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]101
- Special Emphasis Panel[ZRG1 OTC-T (10)]81
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]48
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC15
- L2 DIAGNOSTICS, LLC13
- MEDOSOME BIOTEC, LLC10
- ARREVUS, INC.7
- MICROBIOTIX, INC7
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities2R42MD015915-02 | SHAH, SWATI | FETAL LIFE, LLC, KY | $1,022,015 | ZRG1 |
| 2022 | Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin2R42CA243954-02 | SHAFIRSTEIN, GAL | POP BIOTECHNOLOGIES, INC, NY | $1,001,404 | ZRG1 |
| 2022 | Development of a novel accurate therapy for multiple sclerosis2R42AI141323-02A1 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $1,000,000 | ZRG1 |
| 2022 | A method for accurate and sensitive detection of HIV drug-resistant minority variants2R42AI122855-02A1 | WANG, GARY P. | MEDOSOME BIOTEC, LLC, FL | $999,999 | ZRG1 |
| 2022 | Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections2R42AI145759-03 | SPELLBERG, BRAD J | EXBAQ LLC, MD | $995,098 | ZRG1 |
| 2022 | A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR12R42AI142846-03 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $988,360 | ZRG1 |
| 2022 | Mitofusin Agonists to Treat Neurodegenerative Disease2R42NS113642-03 | DORN, GERALD W.HAUGER, DEBORAH ANN | MITOCHONDRIA IN MOTION, INC., MO | $968,715 | ZRG1 |
| 2022 | Teleconsent: Enabling informed consent for remote care and research2R42TR004277-02 | WELCH, BRANDON M | DOXY.ME, LLC, SC | $863,404 | ZRG1 |
| 2022 | Novel methods to improve nuclease mediated homologous recombination2R42GM122181-02 | ZHANG, JIFENG | ATGC, INC., MI | $854,843 | ZRG1 |
| 2022 | VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction1R41HL162161-01 | SPEES, JEFFREY L | SAMBA BIOLOGICS INCORPORATED, VT | $498,271 | ZRG1 |
| 2022 | Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome1R41MH128993-01 | REN, BING | EPIGENOME TECHNOLOGIES, INC., CA | $450,000 | ZRG1 |
| 2022 | Development of the GlycoHCCTyper for the early detection of HCC1R41CA268268-01 | CASTELLINO, STEPHENMEHTA, ANAND S. | GLYCOPATH, INC, SC | $428,443 | ZRG1 |
| 2022 | Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment1R41CA268623-01 | NGWA, WILFREDSHILLING, ADAM | NANOCAN THERAPEUTICS CORPORATION, NJ | $400,000 | ZRG1 |
| 2022 | Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancer1R41CA268344-01 | DRAKE, JUSTIN MICHAELPARTHASARATHY, JAYANT | ASTRIN BIOSCIENCES, INC., MN | $399,678 | ZRG1 |
| 2022 | Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer1R41CA268300-01 | KORNBLUTH, JACKI | VANQUISH BIO LLC, FL | $399,580 | ZRG1 |
| 2022 | Development of a small-molecule immunomodulator for the treatment of melanoma1R41CA261311-01A1 | VAN DROSS, RUKIYAH | CLARADELE PHARMACEUTICALS, INC., NC | $398,242 | ZRG1 |
| 2022 | High-speed, portable reflectance confocal microscope (pRCM) for imaging skin cancer1R41CA261214-01A1 | KANG, DONGKYUN | ARGOSMD, INC., CA | $398,209 | ZRG1 |
| 2022 | Development of Novel CD180-Based Cancer Immunotherapeutics1R41CA257531-01A1 | CLARK, EDWARD AFULLER, DEBORAH H. | ABACUS BIOSCIENCE INC, WA | $398,040 | ZRG1 |
| 2022 | Development of Therapeutic Cancer Vaccine1R41CA265459-01 | SHEN, HAIFA | IMMUNOQ THERAPEUTICS INC., TX | $395,738 | ZRG1 |
| 2022 | Development of novel pharmacotherapies for AUD1R41AA029365-01A1 | ANDERSON, ETHAN MICHAELCOWAN, CHRISTOPHER W | NEUROEPIGENIX, LLC, SC | $392,942 | ZRG1 |
| 2022 | Profiling circulating metabolites for the diagnosis of pulmonary hypertension1R41HL158296-01A1 | RAFIKOVA, OLGA | METFORA LLC, AZ | $373,684 | ZRG1 |
| 2022 | Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery1R41HL162397-01 | MARSDEN, ALISON LWILSON, NATHAN MARSHALL | BIOGRAFT, INC., CA | $345,103 | ZRG1 |
| 2022 | Improved Diagnosis of Shunt Malfunction with Automatic Quantification of Ventricular Space1R41NS125874-01 | FENG, XUE | CARINA MEDICAL, LLC, VA | $339,999 | ZRG1 |
| 2022 | Rusalatide Acetate (TP508) Mitigation of Genotoxic Radiation Damage in Human Lens Epithelial Cells1R41EY033583-01 | ANDLEY, USHA PFRANK, STEVEN JAY | AFFIRMED PHARMA, LLC, TX | $327,510 | ZRG1 |
| 2022 | Implementation and validation of a lung x-ray interferometry imaging system, with applications to COPD, COVID-19 and other lung diseases1R41HL158414-01A1 | MATTHEWS, KENNETH L | REFINED IMAGING, LLC, LA | $322,996 | ZRG1 |
| 2022 | Development of a Gectosome Therapy for Cardiovascular Diseases1R41HL162212-01 | LIU, XUEDONG | VESICLE THERAPEUTICS INC., CO | $316,823 | ZRG1 |
| 2022 | Real-Time Quantitation of Transport Across Vascular-Tissue Interfaces in Organ-On-Chip Models Using In Situ Mass Spectrometry1R41GM145196-01 | GERMAN, CARRIE | CFD RESEARCH CORPORATION, AL | $314,215 | ZRG1 |
| 2022 | Rapid Drug Susceptibility Test for Tuberculosis1R41AI167101-01 | CIRILLO, JEFFREY D. | PULMONESCENCE DIAGNOSTICS, INC., TX | $306,500 | ZRG1 |
| 2022 | Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery1R41AI167166-01 | FLANK, SHARONSOCHOL, RYAN DANIEL | INFRATRAC, INC., MD | $303,714 | ZRG1 |
| 2022 | A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections1R41AI167078-01 | HARDING, CHRISTIAN | VAXNEWMO, LLC, MO | $300,000 | ZRG1 |
| 2022 | Novel Peptide Fusion Inhibitors for the Treatment of COVID-191R41AI162083-01A1 | TARRAN, ROBERT | ELDEC PHARMACEUTICALS, INC., NC | $300,000 | ZRG1 |
| 2022 | Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide1R41AI167270-01A1 | BARBER, GLEN N | STINGINN, LLC, FL | $300,000 | ZRG1 |
| 2022 | The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption1R41CA268293-01 | FLYNN, RYAN THOMAS | PXALPHA, LLC, IA | $300,000 | ZRG1 |
| 2022 | Treatment of Inflammatory Complications of Viral Pneumonia1R41AI162590-01A1 | AGRAWAL, ANDY | RESPANA THERAPEUTICS, INC., PA | $300,000 | ZRG1 |
| 2022 | Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction1R41AI167172-01 | DU, YANMING | HARLINGENE LIFE SCIENCES LLC, PA | $300,000 | ZRG1 |
| 2022 | CCR5 immunotoxins as components of HIV cure regimens1R41AI165350-01A1 | HARTIGAN-O'CONNOR, DENNIS J. | TENDEL THERAPIES INC., CA | $300,000 | ZRG1 |
| 2022 | Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings1R41AI162258-01A1 | STEVENSON, MARIO | DISCIDIUM BIOSCIENCES, LLC, FL | $299,999 | ZRG1 |
| 2022 | AIDen: An AI-empowered detection and diagnosis system for jaw lesions using CBCT1R41DE031485-01 | LI, JINGLURE, FLEMING Y. M.SETZER, FRANK CARSTEN MARTIN | MS TECHNOLOGIES CORPORATION, MD | $299,987 | ZRG1 |
| 2022 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis1R41HL162392-01 | KNOX, KENNETH SMARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $299,905 | ZRG1 |
| 2022 | A rapid test for congenital syphilis screening1R41HD107895-01 | FRALEY, STEPHANIE IRENESINHA, MRIDU | MELIOLABS INC., CA | $299,891 | ZRG1 |
| 2022 | F plus G RSV VLP Vaccine for Improved Safety and Efficacy1R41AI167226-01 | ANDERSON, LARRY J | RAZI PHARMA LLC, GA | $299,791 | ZRG1 |
| 2022 | Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate1R41AI162366-01A1 | PANG, XIAOWU | TENGEN BIOMEDICAL CO., MD | $298,530 | ZRG1 |
| 2022 | Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury1R41AI155327-01A1 | AKERLEY, BRIAN | ADVAC THERAPEUTIC, LLC, PA | $296,926 | ZRG1 |
| 2022 | Solving Sepsis: Early Identification and Prompt Management Using Machine Learning1R42GM144999-01 | PATEL, MANESH R | COHERE-MED, INC., CA | $275,766 | ZRG1 |
| 2022 | Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapies1R41EY033603-01 | HIRSCH, MATTHEW LOUIS | EPIGENOS BIOSCIENCE, INC., NC | $263,372 | ZRG1 |
| 2022 | Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage1R41NS122656-01A1 | BROPHY, COLLEEN M | VASAMETRIX LLC, TN | $261,863 | ZRG1 |
| 2022 | Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability1R42HL162214-01 | FEDERICI, CHIARAGURKAN, UMUT A. | BIOCHIP LABS, INC., OH | $259,611 | ZRG1 |
| 2022 | Point-of-care microdevices for simultaneous detection of multiple pertussis-like respiratory diseases from Bordetella species1R41AI162477-01A1 | LI, XIUJUN | MICROBIOCHIP DIAGNOSTICS LLC, TX | $259,565 | ZRG1 |
| 2022 | Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design1R41HL162242-01 | NANDI, SEEMA | SELSYM BIOTECH, INC., NC | $258,501 | ZRG1 |
| 2022 | Reduction of Pigmentation Dependent Errors using Spectroscopic Pulse Oximetery1R41GM142406-01A1 | KHURANA, VIKASPATIL, CHETAN A | AIMLOXY LLC, PA | $256,571 | ZRG1 |
| 2022 | Assessment of mobile application-delivered lighting interventions for reducing circadian disruption in shift workers1R41HL163783-01A1 | CHENG, PHILIPWALCH, OLIVIA | ARCASCOPE, INC, VA | $254,877 | ZRG1 |
| 2022 | Optimal adjuvant/antigen formulation toward a Staphylococcus aureus human vaccine1R41AI167268-01 | MISSIAKAS, DOMINIQUE M. | IMMUNARTES LLC, IL | $253,925 | ZRG1 |
| 2022 | Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening1R42ES033912-01 | ASHTON, RANDOLPH SCOTT | NEUROSETTA LLC, WI | $199,800 | ZRG1 |
| 2022 | The BioGradMatch Program1R41GM145182-01 | JOSH, LEVINEWARRICK, CYNTHIA A | ADMIT ACADEMY LLC, TX | $149,957 | ZRG1 |
| 2021 | Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment2R42NS098918-02A1 · under PA-19-270 | BOOHER, KEITHGUO, WEIHUANG, SHAOLING | ZYMO RESEARCH CORPORATION, CA | $1,082,714 | ZRG1 |
| 2021 | Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A2R42NS115184-02 | DORN, GERALD W. | MITOCHONDRIA IN MOTION, INC., MO | $1,059,214 | ZRG1 |
| 2021 | SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps2R42HD097831-02 | KHEIR, JOHN NAGI | CONTECH MEDICAL, INC., RI | $1,036,191 | ZRG1 |
| 2021 | Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles2R42AI155031-02 | ATHANASIOU, MARIA CONSTANCESKINNER, PAMELA J | MARPAM PHARMA, LLC, MN | $1,018,997 | ZRG1 |
| 2021 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses2R42AI138630-03 | HARTY, RONALD N | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,017,000 | ZRG1 |
| 2021 | Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)2R42CA239853-02A1 | HAWKINS, WILLIAM GKELLER, BRADLEY T. | ACCURONIX THERAPEUTICS, INC., MO | $1,014,729 | ZRG1 |
| 2021 | Small-molecule therapy for metastatic castration-resistant prostate cancer2R42CA217491-02A1 | WU, DAQING | METCURE THERAPEUTICS, LLC, GA | $1,007,817 | ZRG1 |
| 2021 | Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)2R42AI129119-03 | PANG, XIAOWU | TENGEN BIOMEDICAL CO., MD | $1,000,000 | ZRG1 |
| 2021 | Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.2R42AI138623-03A1 | KHUONG, NHIMURPHY, SEAN C | LUMEN BIOSCIENCE, INC., WA | $1,000,000 | ZRG1 |
| 2021 | Aminoglycosides with reduced ototoxicity2R42AI126874-03 · under PA-19-270 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $999,986 | ZRG1 |
| 2021 | Development of peptide nucleic acid antibiotics2R42AI114114-03 · under PA-19-270 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $999,985 | ZRG1 |
| 2021 | Isovolumetric Multimodal Venous Thrombectomy System2R42HL150963-02A1 | LIEKWEG, STACEYZAYED, MOHAMED A. | CAELI VASCULAR, LLC, MO | $981,043 | ZRG1 |
| 2021 | A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy2R42DK117684-02A1 | BAKER, LISA ANNDAVIES, KELVIN PSHARP, DAVID JAMES | MICROCURES, INC., CA | $941,635 | ZRG1 |
| 2021 | Multi-Institutional Implementation of Quality Decisions: a Clinical Decision Support Analytics Tool to Drive Outcomes2R42LM013317-02 · under PA-19-270 | ORENSTEIN, EVAN WILLIAM | PHRASE HEALTH, INC., PA | $872,808 | ZRG1 |
| 2021 | Chitosan Endoluminal Hemostatic Dressing2R42DK078400-05 | MCCARTHY, SIMON JOHNXIE, HUA | TRICOL BIOMEDICAL, INC., OR | $853,858 | ZRG1 |
| 2021 | Imaging biomarkers of severe respiratory infections in premature infants Phase II2R42HL145669-02A1 · under PA-19-270 | ENQUOBAHRIE, ANDINET ASMAMAWLINGURARU, MARIUS GEORGENINO, GUSTAVO | KITWARE, INC., NY | $852,101 | ZRG1 |
| 2021 | STTR Phase II: Advance Early Detection of Lupus Nephritis with ClearGold2R42DK123943-02A1 | YU, MENGXIAO | CLEARNANO, INC., TX | $809,923 | ZRG1 |
| 2021 | Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations2R42AG059475-02A1 | FRITZ, STACY LYNNE | ADVANCED SMART SYSTEMS/EVALUATION TECHNO, SC | $740,205 | ZRG1 |
| 2021 | Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors2R44DK121587-02 | DRAGANSKI, ANDREW R | ZYLO THERAPEUTICS, INC., SC | $697,168 | ZRG1 |
| 2021 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma2R42CA240124-02 | MARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $674,537 | ZRG1 |
| 2021 | Affordable sialoglycans and associated reagents for expanded chemoenzymatic production1R42GM143998-01 | LEE, LIM ANDREW | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC., SC | $640,000 | ZRG1 |
| 2021 | Enabling rapid and effective stroke thrombectomy procedures from a Transradial approach: Combining introducer sheath, guide catheter, and distal access catheter into a single device.1R41NS122602-01 | KALLMES, DAVID F | CONWAY MEDICAL LLC, MN | $490,053 | ZRG1 |
| 2021 | A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-12R42AG061909-02A1 | BEINBORN, MARTINKUMAR, KRISHNA | VELUM, INC., MA | $488,486 | ZRG1 |
| 2021 | NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice1R41NS124450-01 | MORRISON, HELENA WILLINGTONUNGER, EVAN CHARLES | NUVOX PHARMA, LLC, AZ | $478,050 | ZRG1 |
| 2021 | HBI-002 to Treat Parkinson’s Disease1R41NS122576-01 | GOMPERTS, EDWARDGOMPERTS, STEPHEN N. | HILLHURST BIOPHARMACEUTICALS, INC., CA | $453,158 | ZRG1 |
| 2021 | VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies1R41HL152919-01A1 · under PA-19-270 | SHAFFER, ROBERTWANG, XUEJUN | ENABLE THERAPEUTICS LLC, MA | $450,022 | ZRG1 |
| 2021 | A New Anti-inflammatory Therapy for Ischemic Stroke1R41HL156322-01 · under PA-19-270 | LIANG, BRUCE | CORNOVUS PHARMACEUTICALS, INC., CT | $433,483 | ZRG1 |
| 2021 | Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain1R41NS122545-01A1 | KHANNA, RAJESH | REGULONIX, LLC, NY | $419,470 | ZRG1 |
| 2021 | Multi-modal cloud based system for detecting early signs of driver cognitive decline and/or high risk driving behaviors1R41AG073222-01 | MAGULURI, GOPI N | PHYSICAL SCIENCES, INC, MA | $416,423 | ZRG1 |
| 2021 | Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis1R41CA250757-01A1 · under PA-19-270 | ALLEN, THADDEUS DAVID | TRADEWIND BIOSCIENCE, INC., CA | $405,552 | ZRG1 |
| 2021 | Engineered adipokine receptor inhibitor for the treatment of triple negative breast cancer in obese patients1R41CA257425-01 · under PA-19-270 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $400,000 | ZRG1 |
| 2021 | Development of small molecule epigenetic therapeutics for prostate cancer1R41CA261384-01 | AHN, JUNG-MOHSIEH, JER-TSONGLIU, ZHI-PING | RAPHAEL PHARMACEUTICALS LLC, TX | $400,000 | ZRG1 |
| 2021 | CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma1R42CA261547-01 | WANG, ZHIRUI | ROCK IMMUNE LLC, CO | $400,000 | ZRG1 |
| 2021 | Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma1R41CA254492-01A1 | GARRISON, JERED C | ADDUCTNE, LLC, NE | $400,000 | ZRG1 |
| 2021 | Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis1R41CA257262-01A1 | RATHMACHER, JOHN AWILSON, KEITH T. | MTI BIOTECH, INC., IA | $400,000 | ZRG1 |
| 2021 | A New Class of Magnetic Nanoparticles for Glioma Targeted Drug Delivery1R41CA261544-01 | LI, YUANCHENGMAO, HUI | 5M BIOMED, LLC, GA | $400,000 | ZRG1 |
| 2021 | Development of a radiation-activatable nanoparticle for lung cancer therapy1R41CA257584-01A1 | LIU, ZHI | ATHNA BIOTECH, INC., GA | $400,000 | ZRG1 |
| 2021 | Inhibition of CaVα-β interaction with orally available small organic molecules for chronic pain1R41CA257845-01A1 | KHANNA, RAJESH | REGULONIX, LLC, NY | $400,000 | ZRG1 |
| 2021 | Fingerprinting Cancer via Multiparameter Extracellular Vesicle Analysis1R41CA265607-01 | GERMAN, SEAN | ELECTRONIC BIOSCIENCES, INC., CA | $400,000 | ZRG1 |
| 2021 | An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.1R41CA265655-01 | MUKHERJEE, PINKUZHOU, RU | ONCOTAB, INC, NC | $400,000 | ZRG1 |
| 2021 | SIRPant Technology for anti-Cancer Immunity1R42CA265691-01 | MCCURLEY, NATHANAEL | SIRPANT IMMUNOTHERAPEUTICS, INC., PA | $400,000 | ZRG1 |
| 2021 | Non-invasive neurosurgical planning with Random Matrix Theory MRI1R41CA257624-01A1 | LEMBERSKIY, GRIGORIY | MICROSTRUCTURE IMAGING, INC., NY | $399,999 | ZRG1 |
| 2021 | Long-lived Platform Development for Exonuclease-Based Sequencing1R41HG012163-01 | ERVIN, ERIC | ELECTRONIC BIOSCIENCES, INC., CA | $399,999 | ZRG1 |
| 2021 | Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs1R41CA265583-01 | ELIASOF, SCOTT D | CULNEXIN THERAPEUTICS, INC., NJ | $399,999 | ZRG1 |
| 2021 | Neupron™: A Neuroprotective Agent for Treating Acute Spinal Cord Injury1R41NS122587-01 | LABHASETWAR, VINOD D | AXONEURAL THERAPEUTICS, INC., OH | $399,987 | ZRG1 |
| 2021 | Development of a biomarker panel for screening and early detection of gynecological cancers1R41CA257115-01 · under PA-19-270 | MARTIGNETTI, JOHN A | MDDX, INC., NY | $399,972 | ZRG1 |
| 2021 | Development of Drug Detoxifying Bacteria for Chemotherapy Induced Gut Injury1R41CA261292-01 | HU, MINGSINGH, RASHIMWANG, XIAOQIANG | SANARENTERO LLC, TX | $399,955 | ZRG1 |
| 2021 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.1R41CA265512-01 | BAR-SAGI, DAFNAKOIDE, SHOHEIRAMIREZ, CRAIG PATRICK | TEZCAT LABORATORIES LLC, CT | $398,715 | ZRG1 |
| 2021 | Same-day Breast Pathology Results using Open-Top Light-Sheet Microscopy for Image-guided Core Needle Biopsies1R41CA261263-01 | REDER, NICHOLAS | ALPENGLOW BIOSCIENCES, INC., WA | $398,305 | ZRG1 |
| 2021 | Cancer Immunotherapy Targeting Tn Antigen1R41CA261408-01A1 | DEMETRIOU, MICHAELZHOU, RAYMOND WENHOU | GLYTR THERAPEUTICS, INC., CA | $398,178 | ZRG1 |
| 2021 | Improved Treatment of Colorectal Cancer with CF101R41CA254834-01A1 | GMEINER, WILLIAM H. | DEEP CREEK PHARMA, LLC, NC | $396,429 | ZRG1 |
| 2021 | A novel polymer-metal nanocomplex for ovarian cancer treatment1R41CA254500-01A1 · under PA-19-270 | XU, PEISHENG | ACEPRE, LLC, SC | $392,803 | ZRG1 |
| 2021 | Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution1R41CA261259-01 | LEE, HSIAOJU SHARONSCHWARZ, SALLY WAGNER | TREVARX BIOMEDICAL, INC., PA | $390,058 | ZRG1 |
| 2021 | Structure Based Design of Pol-theta inhibitors1R41CA265430-01 | POMERANTZ, RICHARD T | RECOMBINATION THERAPEUTICS, LLC, PA | $385,900 | ZRG1 |
| 2021 | Identifying novel targets for cardioprotection with non-traditional animal models1R41HG011577-01 · under PA-19-270 | GOODMAN, LINDA BOETTGER | FAUNA BIO INCORPORATED, CA | $373,434 | ZRG1 |
| 2021 | Multi-path DCS as a novel non-invasive treatment for amyotrophic lateral sclerosis1R41NS125872-01 | AHMED, ZAGHLOUL | PATHMAKER NEUROSYSTEMS, INC., MA | $371,628 | ZRG1 |
| 2021 | Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma1R41CA265624-01 | DOLLOFF, NATHAN G. | LEUKOGENE THERAPEUTICS, INC., SC | $362,118 | ZRG1 |
| 2021 | Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy1R41HL160429-01 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $361,774 | ZRG1 |
| 2021 | A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient Satisfaction2R42NR017124-02 · under PA-19-270 | HAHNE, JEANNE | FACEVIEW MASK, LLC, OR | $359,907 | ZRG1 |
| 2021 | Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN1R41CA261451-01A1 | RIEGER, SANDRA | AVANTYX, LLC, FL | $355,723 | ZRG1 |
| 2021 | Site-specific epigenetic activation of TP53 to improve cancer therapy1R41GM146326-01A1 | HATHAWAY, NATHANIEL A. | EPIGENOS BIOSCIENCE, INC., NC | $350,000 | ZRG1 |
| 2021 | Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissues1R41GM146269-01 | PUSHKARSKY, IVANTSENG, PETER | FORCYTE BIOTECHNOLOGIES, INC., CA | $350,000 | ZRG1 |
| 2021 | The Nanopore-based Ion Selective Electrode Vial1R41GM144015-01 | GERMAN, SEAN | ELECTRONIC BIOSCIENCES, INC., CA | $350,000 | ZRG1 |
| 2021 | AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma1R41GM146327-01 | HUANG, CHUN-HAO | ALGEN BIOTECHNOLOGIES INC, CA | $350,000 | ZRG1 |
| 2021 | Treatment of liver fibrosis with oral hepatic stable and non-genotoxic HDAC inhibitors1R41DK130707-01 | CHOU, CHUNG-JEN JAMESZHONG, ZHI | LYDEX PHARMACEUTICALS, LLC, SC | $349,908 | ZRG1 |
| 2021 | A novel approach to restricting the spread of neurofibrillary tau1R41AG073080-01A1 | KOSIK, KENNETH STEPHENSTILES, TRAVIS LEE | NOVORON BIOSCIENCE, INC., CA | $349,580 | ZRG1 |
| 2021 | Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.1R43HG011608-01 · under PA-19-270 | BRUECK, STEVEN | ARMONICA TECHNOLOGIES, INC., NM | $349,200 | ZRG1 |
| 2021 | New Treatments for Glaucoma1R41EY033263-01 | MISHRA, SANKET | GRANNUS THERAPEUTICS LLC, IN | $346,562 | ZRG1 |
| 2021 | An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practice1R41HL160362-01 | SCHILLING, JAMES W | MPROBE, INC., CA | $346,545 | ZRG1 |
| 2021 | Targeting the Integrated Stress Response effector ATF4 for mitigation of treatment-induced fibrosis1R41CA261378-01A1 | KOUMENIS, CONSTANTINOSSIELECKI, THAIS MOTRIA | VELTION THERAPEUTICS LLC, PA | $335,671 | ZRG1 |
| 2021 | Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease1R41EY033262-01 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $328,150 | ZRG1 |
| 2021 | Computational prediction of gut microbiome-mediated drug metabolism1R41TR003571-01A1 | MOFRAD, MOHAMMAD RKSHIRAZI, FATEMEHSOHEILYPOUR, MOHAMMAD | NEXILICO, INC., CA | $325,000 | ZRG1 |
| 2021 | Bioengineering a Novel Therapeutic Transporter that Crosses the Blood Brain Barrier to Treat Brain Disorders1R41TR003960-01A1 | KLEMKE, RICHARD L. | CYTONUS THERAPEUTICS, INC., OH | $324,986 | ZRG1 |
| 2021 | Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy1R43CA257108-01A1 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $324,675 | ZRG1 |
| 2021 | Bronchoscopic lung navigation system for accurately excising lung nodules1R41CA261420-01A1 | JAGADEESAN, JAYENDER | NAVIGATION SCIENCES, INC., MA | $324,002 | ZRG1 |
| 2021 | Engineering a long-acting relaxin agonist to treat liver fibrosis1R41DK131681-01 | AGOULNIK, ALEXANDER IAGOULNIK, IRINADISTEFANO, PETER SLINDSAY, RONALD | ZEBRA BIOLOGICS, INC., MA | $308,708 | ZRG1 |
| 2021 | 3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection1R41GM146268-01 | MCENTIRE, BRYAN J. | SINTX TECHNOLOGIES, INC., UT | $308,301 | ZRG1 |
| 2021 | On-chip filtration and fractionation components for high-sensitive POC device to measure Chiral Metabolites in Urine1R41GM143348-01 | HEJAZI, LEILAZHANG, GUANSHI | SYGNAMAP, INC., TX | $307,230 | ZRG1 |
| 2021 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum1R41AI162385-01 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $306,500 | ZRG1 |
| 2021 | Removable airway stents that preserve mucociliary function1R41HL158451-01 | DUPONT, PIERRE EKAZA, ADITYA K | DOWN FROM THE DOOR, LLC, NC | $303,769 | ZRG1 |
| 2021 | Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotics LR-IL-22 and LR-IFN-β1R41AI157357-01 · under PA-19-270 | GREENBERGER, JOEL SROGERS, CLAUDE J. | CHROMOLOGIC, LLC, CA | $300,000 | ZRG1 |
| 2021 | Use novel natural compound Sparstolonin B to treat bacterial sepsis1R41AI157378-01 · under PA-19-270 | FAN, HONGKUAN | ACEPRE, LLC, SC | $300,000 | ZRG1 |
| 2021 | Small molecule inhibitors of influenza virus nucleoprotein1R41AI162408-01 | ENGEL, DANIEL A | ALEXANDER BIODISCOVERIES, LLC, VA | $300,000 | ZRG1 |
| 2021 | Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics1R42AI155039-01A1 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $300,000 | ZRG1 |
| 2021 | Targeting Covid-19 with a Therapeutic Interfering Particle1R41AI157129-01A1 | ANDINO, RAUL | ALEPH THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2021 | Gene therapy to treat glaucoma by reducing intraocular pressure1R41EY033238-01 | DANIAS, JOHN | ADVANCED VISION TECHNOLOGIES, NY | $300,000 | ZRG1 |
| 2021 | Pulmonary Surface Irregularity score: A Quantitative CT Biomarker for Idiopathic Pulmonary Fibrosis1R41GM146329-01 | JACOBUS, ROBERT B | AI METRICS, LLC, AL | $299,999 | ZRG1 |
| 2021 | Biomimetic size-adaptable heart valve for prosthesis-patient mismatch1R41HL156563-01 · under PA-19-270 | DEL NIDO, PEDRO J. | AUTUS VALVE TECHNOLOGIES, INC., MA | $299,994 | ZRG1 |
| 2021 | Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-21R41AI157626-01 · under PA-19-270 | HARTIGAN-O'CONNOR, DENNIS J. | TENDEL THERAPIES INC., CA | $299,983 | ZRG1 |
| 2021 | Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry1R41AI157717-01 · under PA-19-270 | O'CONNELL, MITCHELL | DAHLIA BIOSCIENCES, INC., CA | $299,978 | ZRG1 |
| 2021 | A dual-acting small molecule for the treatment of type 1 diabetes1R41DK131839-01 | BAHAMONDES LORCA, VERONICA ANDREANUNEMAKER, CRAIG S | ASAKE BIOTECHNOLOGY, LLC, OH | $299,974 | ZRG1 |
| 2021 | Small Intestine Targeted Fast Acting Oral Insulin Formulation1R41DK131761-01 | LI, YUANCHENGMAO, HUI | 5M BIOMED, LLC, GA | $299,931 | ZRG1 |
| 2021 | A Novel Broad-spectrum Antiviral Agent1R41AI157527-01 · under PA-19-270 | BOTTEN, JASON W.MURAD, JOANA M | CELDARA MEDICAL, LLC, NH | $299,916 | ZRG1 |
| 2021 | HBI-002 to Treat Diabetic Retinopathy1R41EY033264-01 | GOMPERTS, EDWARDJADEJA, RAVIRAJSINHMARTIN, PAMELA M | HILLHURST BIOPHARMACEUTICALS, INC., CA | $299,899 | ZRG1 |
| 2021 | Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes1R42HL158510-01 | PRICE, JEFFREY H. | VALA SCIENCES, INC., CA | $299,871 | ZRG1 |
| 2021 | Phospholipid antimetabolite lipid ether amines for topical treatment of chronic wounds and associated biofilms.1R41DK127900-01A1 | GIBSON, DANIEL JSVETLOV, ARTEM S | INTEGUMED, LLC, FL | $299,749 | ZRG1 |
| 2021 | Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery1R41HL160434-01 | JAFFER, FAROUC AMINSEWARD, KIRK | MERCATOR MEDSYSTEMS, INC., CA | $299,678 | ZRG1 |
| 2021 | Translation of Interferometric-based Free-solution Assay Methodology1R41GM139497-01A1 | BORNHOP, DARRYL J.RODENHAVER, DANIEL | MERU BIOTECHNOLOGIES, INC., VA | $299,661 | ZRG1 |
| 2021 | Translational imaging tools to nondestructively measure nephron mass1R41DK129138-01A1 | BENNETT, KEVIN M | XN BIOTECHNOLOGIES, LLC, MO | $299,633 | ZRG1 |
| 2021 | Furopyrimidines as novel inhibitors of henipaviruses1R41AI157095-01 · under PA-19-270 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $299,595 | ZRG1 |
| 2021 | A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 11R41AI157014-01A1 | NARASIMHAN, SUKANYA | L2 DIAGNOSTICS, LLC, CT | $299,514 | ZRG1 |
| 2021 | Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers1R41CA261407-01A1 | LEOPOLD, JUDITH SWHITEHEAD, CHRISTOPHER EMIL | MEKANISTIC THERAPEUTICS, LLC, MI | $299,503 | ZRG1 |
| 2021 | Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection1R41AI157287-01A1 | AVCI, FIKRI Y | PNEUMOTACTIX, LLC, GA | $299,450 | ZRG1 |
| 2021 | Thermostable Inactivated Potent Yellow Fever Vaccine1R41AI165205-01 | AGUILAR, PATRICIA VERONICABRONSHTEIN, VICTOR | UNIVERSAL STABILIZATION TECHNOLOGIES, CA | $299,380 | ZRG1 |
| 2021 | Rapid Genetic Fingerprinting of SARS-Cov-2 Variants1R41AI162575-01A1 | SAMADPOUR, MANSOURSOKURENKO, EVGENI VENIAMINOVIC | IDGENOMICS, INC., WA | $299,200 | ZRG1 |
| 2021 | Novel therapeutic target to combat cutaneous lupus1R41TR003929-01A1 | ASTRUC DIAZ, FANNY | DERMAXON, LLC, MT | $298,132 | ZRG1 |
| 2021 | Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)1R41NS122647-01 | KAUFMANN, GUNNAR JOERG FLORIS | ONCTERNAL THERAPEUTICS, INC., CA | $297,671 | ZRG1 |
| 2021 | Development of Small Molecule Antagonists of PAR-2 for treatment of asthma1R41HL160424-01 | BOITANO, SCOTTDEFEA, KATHRYN ANNE | PARMEDICS, INC., CA | $283,387 | ZRG1 |
| 2021 | COVID-19: High Efficiency SARS-CoV-2 Virus Aerosol Sampling and Sensing1R41AI157347-01A1 | KEADY, PATRICIA BEA | AEROSOL DEVICES, INC., CO | $262,802 | ZRG1 |
| 2021 | The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma1R41CA265619-01 | MUKHERJEE, PINKUZHOU, RU | ONCOTAB, INC, NC | $260,588 | ZRG1 |
| 2021 | Triagonist Peptide Therapeutics for Neuroprotection1R41GM142448-01A1 | KUMAR, KRISHNA | VELUM, INC., MA | $259,613 | ZRG1 |
| 2021 | Diamond NMR spectrometer for microfluidic metabolite profiling1R41GM145129-01 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $259,000 | ZRG1 |
| 2021 | Development of a Vaccine for Staphylococcal Infections1R41AI157087-01A1 | MISSIAKAS, DOMINIQUE M. | IMMUNARTES LLC, IL | $257,842 | ZRG1 |
| 2021 | Antibacterial nanoparticles as insecticide synergists and insect growth regulators for improved control of cockroach infestations1R41AI162017-01 | PIETRI, JOSE ENRIQUE | APEX BAIT TECHNOLOGIES, INC., CA | $257,554 | ZRG1 |
| 2021 | Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage1R41GM140538-01 · under PA-19-270 | JOHNSON, STEVEN EDWARD | DURAMETRIX LLC, WI | $257,175 | ZRG1 |
| 2021 | Designing an Adolescent Centered Cards on the Table Toolkit1R41HD104324-01A1 | CHOR, JULIEPARSONS, TIMOTHY | RESILIENT GAMES STUDIO, LLC, IL | $256,937 | ZRG1 |
| 2021 | Computer-aided design for improved lantibiotics1R41GM136034-01A1 · under PA-19-270 | HANDFIELD, MARTIN | ORAGENICS, INC., FL | $256,654 | ZRG1 |
| 2021 | Heteroduplex thermostable ligation assembly: a new platform to rapidly generate large DNA molecules1R41GM145048-01 | BIEBERICH, CHARLES J. | CHESAPEAKE GENOMIC SYSTEMS LLC, MD | $256,645 | ZRG1 |
| 2021 | Enabling Next Generation Machine Learning for Large Scale Image Analysis1R41EB032722-01 | SABIN, GERALD | RNET TECHNOLOGIES, INC., OH | $256,581 | ZRG1 |
| 2021 | An Innovative Screener for Reading and SLI targeting Kindergarten through 3rd Grade Students1R43DC018766-01A1 · under PA-19-270 | ANGEL, MARKRICE, MABEL L | AMIRA LEARNING, INC., CA | $256,580 | ZRG1 |
| 2021 | Novel Ophthalmic Product for Corneal Infections and Injuries1R41EY032437-01 · under PA-19-270 | PEREIRA, HELOISE ANNE | BIOLYTX PHARMACEUTICALS CORP, OK | $256,580 | ZRG1 |
| 2021 | Use of polymer-peptide system to deliver cells for intervertebral disc regeneration1R41AR079324-01 | SILVA, FRANCISCO J | BIORESTORATIVE THERAPIES, INC., NY | $256,580 | ZRG1 |
| 2021 | Development of Safe in Utero Gene Editing Technology in Mice1R41TR003752-01 | RABUKA, DAVID | ACRIGEN BIOSCIENCES, INC., CA | $256,580 | ZRG1 |
| 2021 | 2-HOBA for Treatment of Pulmonary Hypertension1R41HL158393-01 | RATHMACHER, JOHN AWEST, JAMES D | MTI BIOTECH, INC., IA | $256,580 | ZRG1 |
| 2021 | Allosteric Drug Discovery using Quantum Cascade Laser based Anisotropic THz Microscope (QCL-ATM)1R41GM140587-01A1 | LEE, ALAN | LONGWAVE PHOTONICS, LLC, CA | $256,580 | ZRG1 |
| 2021 | Noninvasive challenge-free widely-accessible oxygen extraction fraction mapping1R41NS122675-01A1 | DORFMAN, GARYWANG, YI | MEDIMAGEMETRIC, LLC, NY | $256,580 | ZRG1 |
| 2021 | A Biliary Tract-Specific Fluorescence Image-guided Surgery1R41EB032284-01 | CHA, RICHARD JAEPYEONG | OPTOSURGICAL, LLC, DE | $256,579 | ZRG1 |
| 2021 | Dye-free, multimodal, quantitative imaging to assess bowel perfusion during laparoscopic colorectal resection1R41DK131650-01 | CHA, RICHARD JAEPYEONG | OPTOSURGICAL, LLC, DE | $256,579 | ZRG1 |
| 2021 | Endothelialized microfluidic assays for emerging therapies in sickle cell disease1R42HL160384-01 | FEDERICI, CHIARAGURKAN, UMUT A. | BIOCHIP LABS, INC., OH | $256,578 | ZRG1 |
| 2021 | Universal affinity membrane chromatography for rapid, one-step purification of proteins1R41GM142336-01 | HUSSON, SCOTT M | TRIALTUS BIOSCIENCE, LLC, AL | $256,576 | ZRG1 |
| 2021 | Multistage LC-MSn for automated glycan isomer assignment of glycopeptides1R41GM142363-01 | GUTTMAN, MIKLOS | PROTEIN METRICS, LLC, CA | $256,570 | ZRG1 |
| 2021 | Synthetic Antimicrobial Peptoids for Treatment of Chronic Suppurative Otitis Media1R41DC020077-01 | BARRON, ANNELISE EMILYKIRSHENBAUM, KENT WSANTA MARIA, PETER LUKE | MAXWELL BIOSCIENCES, INC., TX | $256,538 | ZRG1 |
| 2021 | MiGo: wearable sensors that combine actionable data with a behavioral intervention to improve function after stroke1R41HD104296-01A1 | ROWE, JUSTINWINSTEIN, CAROLEE J | FLINT REHABILITATION DEVICES, CA | $256,519 | ZRG1 |
| 2021 | Polymer use in Preservation of Tissue Perfusion to Address Sepsis1R41GM143995-01 | MANGINO, MARTIN J. | PERFUSION MEDICAL, LLC, VA | $256,492 | ZRG1 |
| 2021 | Therapeutic Strategy for NASH1R41DK130765-01 | SELTZMAN, HERBERT H | ARTIAM BIO INC., NC | $256,475 | ZRG1 |
| 2021 | Improved Methods and Commercialization of Native Mass Spectrometry by Capillary Vibrating Sharp-edge Spray Ionization (cVSSI)1R41GM142379-01 | VALENTINE, STEPHEN | INVIBRAGEN INC., WV | $256,452 | ZRG1 |
| 2021 | Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis1R41HL156767-01A1 | KRYMSKAYA, VERA PPLEIMES, DIRK | BIOSPUTNIK LLC, NY | $256,400 | ZRG1 |
| 2021 | Low Cost Spectroscopic OCT for GI Applications1R41EB032693-01 | BROWN, WILLIAM | LUMEDICA, INC., NC | $256,323 | ZRG1 |
| 2021 | Protective film-forming disinfectant based on chitosan/water/ethanol tertiary solutions1R41AI157565-01A1 | VERTEGEL, ALEXEY A | VRM LABS INC, SC | $256,321 | ZRG1 |
| 2021 | Development of Innovative Medical Device Technology for Quantifying Forces during Soft Tissue Manipulation Assessment and Intervention1R41AT011494-01 | ANWAR, SOHELLOGHMANI, MARY TERRY | HEALTH SMART TECHNOLOGIES, INC., IN | $256,129 | ZRG1 |
| 2021 | A Framework for mHealth App Security and Privacy Analysis1R41GM146313-01 | AHAMED, SHEIKH IQBAL | UBITRIX INTERNATIONAL, INC., WI | $256,079 | ZRG1 |
| 2021 | PHMB-Impregnated Acellular Biologic Grafts for Treatment of Third-Degree Burns1R41GM140660-01 · under PA-19-270 | PASHOS, NICHOLAS | BIOAESTHETICS CORPORATION, NC | $256,069 | ZRG1 |
| 2021 | A Smart Assistant for MRI Technologists1R41EB031739-01A1 | MACY, ALANWARFIELD, SIMON K | BIOPAC SYSTEMS, INC., CA | $256,015 | ZRG1 |
| 2021 | Transient Gene Therapy as Broad Spectrum Antiviral1R41AI164999-01 | BOGUNOVIC, DUSAN | LAB11 THERAPEUTICS, LLC, NY | $255,932 | ZRG1 |
| 2021 | Development of an integrated smartphone/resistive nanosensor for onsite biomonitoring of exposure to pesticides1R41ES032388-01A1 | WANG, JUN | NANODIAGNOSTIC TECHNOLOGY, LLC, NC | $255,880 | ZRG1 |
| 2021 | Development of low-cost, field-ready nanobodies against snake venom1R41GM146314-01A1 | CHANG, GEOFFREY ADEMPSEY, DANIEL THOMAS | VENOMYX, INC., CA | $255,869 | ZRG1 |
Showing the 200 most recent of 1,563 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.